Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Redhill biopharma ltd. source : Www.biospace.com save search
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -5.2%
H: 4.9%
C: 3.92%
million direct offering biopharma market
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 1.1%
H: 3.68%
C: 1.65%
talicia patent
RedHill Biopharma Announces $8 Million Registered Direct Offering
Published: 2024-01-25 (Crawled : 21:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -31.9%
H: 0.61%
C: -11.68%
million direct offering biopharma
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
Published: 2024-01-25 (Crawled : 12:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -31.9%
H: 0.61%
C: -11.68%
talicia patent treatment grant
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Published: 2023-12-20 (Crawled : 20:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 9.09%
H: 20.83%
C: -2.78%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.21%
H: 0.15%
C: -1.34%
rhb-107 ebola opaganib show
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - December 12, 2023
Published: 2023-12-12 (Crawled : 14:30) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -2.24%
H: 6.87%
C: 0.76%
nasdaq biopharma
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 6.63%
H: 12.99%
C: 6.78%
rhb-107 covid-19 funding study phase 2
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 14.5%
H: 4.57%
C: -25.64%
ebola disease virus study
RedHill Announces FDA sNDA Approval for Talicia®
Published: 2023-09-18 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 2.39%
H: 0.0%
C: 0.0%
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 14.12%
H: 5.15%
C: -16.39%
talicia fda approval
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
Published: 2023-08-17 (Crawled : 12:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 3.66%
H: 11.76%
C: 9.41%
biopharma financial results
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 1.56%
H: 4.62%
C: -1.54%
rhb-107 covid-19 fda cleared trial platform
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
Published: 2023-07-21 (Crawled : 21:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 5.41%
H: 0.0%
C: -29.74%
direct offering biopharma
Phil and RedHill Biopharma Partner to Increase Access to Talicia®
Published: 2023-07-06 (Crawled : 13:20) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -0.81%
H: 5.74%
C: 2.7%
talicia biopharma
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
Published: 2023-06-12 (Crawled : 15:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -1.63%
H: 5.52%
C: -0.55%
biopharma financial results
RedHill Provides R&D Update
Published: 2023-05-22 (Crawled : 12:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 0.47%
H: 2.35%
C: -2.35%
update
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
Published: 2023-04-28 (Crawled : 12:20) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -3.07%
H: 10.41%
C: 9.95%
biopharma results
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
Published: 2023-04-03 (Crawled : 19:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -1.71%
H: 5.47%
C: -0.5%
direct offering biopharma
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 3.96%
H: 4.32%
C: -3.16%
biopharma opaganib
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
Published: 2023-02-16 (Crawled : 17:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -1.87%
H: 9.52%
C: 8.1%
rhb-102 bekinda meeting application positive
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
Published: 2023-02-16 (Crawled : 17:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: -1.87%
H: 9.52%
C: 8.1%
rhb-102 biopharma meeting positive
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.